The distribution of fleroxacin (Ro 23-6240) in canine prostatic tissue and fluids was investigated under steady-state conditions during intravenous infusion. Mean ratios of fleroxacin concentration in tissue and fluids over concentration in plasma were 1.57 0.25 for prostatic tissue, 1.12 ± 0.28 for prostatic secretion, and 0.93 ± 0.14 for prostatic interstitial fluid. These levels and concentrations in urine were several times higher than the MIC for most pathogens that cause chronic bacterial prostatitis and urinary tract infection. The MICs for several isolates of Escherichia coli were only slightly affected by canine prostatic secretion, human prostatic tissue extract, and human urine. Clinical trials with fleroxacin appear justified for chronic bacterial prostatitis and urinary tract infection.
Chronic bacterial prostatitis may be the most common cause of recurrent urinary tract infection in men (20) . Despite the availability of antimicrobial agents with suitable antibacterial spectra, results of treating chronic bacterial prostatitis have been rather disappointing. The best cure rates reported, using trimethoprim-sulfamethoxazole for 4 to 16 weeks, vary from 32 to 71% (19) .
Fleroxacin (Ro 23-6240 or AM-833) is a newly developed quinolone derivative structurally related to the latest generation of 6-fluoro-7-piperazine-4-quinolones. It has a broad antibacterial spectrum against both gram-positive and gramnegative bacteria, including Pseudomonas aeruginosa and the Enterobacteriaceae (4, 8, 10). Fleroxacin is well absorbed after oral administration in experimental animals (13) , and its long half-life of 9 to 11 h may allow once-per-day dosing (data on file, Hoffmann-La Roche, Inc.). Its antibacterial and pharmacokinetic properties make fleroxacin a potential drug for the treatment of urologic infections, possibly including chronic bacterial prostatitis.
The purpose of this study was to evaluate the distribution of fleroxacin in plasma, prostatic secretion, prostatic interstitial fluid, prostatic tissue, and urine of dogs. We investigated in vitro the influence of dog prostatic secretion, human prostatic tissue extract, and human urine on the antibacterial activity of fleroxacin.
MATERIALS AND METHODS
Animal studies. Fleroxacin was obtained from HoffmannLa Roche, Inc., Nutley, N.J. The dog model used for drug infusion studies has been previously described (15) . Five adult male mongrel dogs weighing 23 to 33 kg were anesthetized intravenously with sodium thiopental. The prostrate was exposed through a low midline abdominal incision, and a multiperforated polyethylene tissue chamber (10 by 6 mm) with two connecting tubes (Engineering Industries, Verona, Wis.) was implanted in each lateral lobe (Fig. 1) . The tubes were irrigated with heparin and placed subcutaneously. Approximately 4 weeks later, the dogs were anesthetized again. The bladder neck was ligated, and a vasectomy was performed to prevent contamination of the prostatic secretion. Prostatic secretion was collected through a transurethrally inserted catheter; prostatic interstitial fluid was obtained from the tissue chambers via the tubes. Urine was collected through a cystostomy. Blood samples were drawn through a cannula inserted in the femoral artery.
To achieve steady-state conditions, fleroxacin was given intravenously as a bolus injection (10 mg/kg of body weight) followed by constant infusion of 1 mg/kg of body weight for 4 h. The infusion rate was doubled in three of the dogs after 3 h and extended to 5 h. To stimulate prostatic secretion, pilocarpine (0.1 mg/kg of body weight) was administered intravenously at intervals as needed. Samples of plasma, urine, prostatic interstitial fluid, and prostatic secretion were collected before drug administration and subsequently at 30-min intervals until the end of the experiment. The dogs were then sacrificed, and specimens from various tissues were taken for bioassay.
All samples were frozen immediately and stored at -17°C until used for bioassay. Fleroxacin concentrations were determined by bioassay, using a disk diffusion method. The test medium was tryptose glucose agar (pH 7.2; GIBCO Diagnostics, Madison, Wis.), and the test organism was Bacillus subtillis ATCC 6633 (Difco Laboratories, Detroit, Mich.). Tissue samples were weighed and then homogenized with an equal volume of phosphate buffer (pH 7.2) by using a Polytron 10 homogenizer (Kinematica GmbH, Luzern, Switzerland), and the supernatant was removed. Urine samples were diluted 1:25 in phosphate buffer (pH 7.2). Plasma, prostatic secretion, and prostatic interstitial fluid were not diluted. Standard curves for plasma were generated from pooled normal dog plasma. A phosphate buffer (pH 7.2) was used for standard curves for prostatic secretion, prostatic interstitial fluid, tissues, and urine. All samples were assayed in triplicate and incubated at 37°C overnight before inhibition zones were measured.
To study the effect of body fluids on the antibacterial activity of fleroxacin, samples of canine prostatic secretion, human prostatic tissue (obtained from patients with benign prostatic hyperplasia, undergoing transurethral resection of the prostate), and human urine were collected. The extract of human prostatic tissue was obtained by homogenizing prostatic tissue with an equal volume of phosphate buffer (pH 7.2) and removing the supernatant. MIC determinations were performed at existing pH levels of fluids and extracts, and all samples were then adjusted to pH 7.0 with 0.1 N sodium hydroxide. The MIC was determined by using a twofold dilution technique with Mueller-Hinton broth plus body fluids and extracts. The final dilutions, containing 105 Escherichia coli per ml (obtained from 12 different patients with urinary tract infection), were incubated overnight at 37°C with the antibacterial agent. At the end of this period, the MIC was defined as the concentration in the last clear well.
For statistical calculations, we employed Student's t test and the Mann-Whitney rank-sum test; P values of <0.05 were considered significant.
RESULTS
All tissue chambers yielded sufficient amounts of fluid every 30 min for bioassay. The prostatic interstitial fluid values are averages for the two chambers. Table 1 shows mean values of fleroxacin concentrations in plasma, prostatic secretion, prostatic interstitial fluid, and urine along with the prostatic secretion/plasma and prostatic interstitial fluid/plasma concentration ratios. Assuming that a steady state had occurred after 1.5 h, the mean concentrations were significantly higher in prostatic secretion than in prostatic interstitial fluid (P <0.001); the prostatic secretion/plasma concentration ratios were constantly above 1. Some dogs had relatively small urine output in the beginning of the study period, which may explain the high urine concentrations recorded from 0.5 to 1.5 h. Various lower genitourinary tissue concentrations and corresponding tissue/plasma concentration ratios are shown in Table 2 . Table 3 
DISCUSSION
This study demonstrated that fleroxacin penetrates well into lower genitourinary tissues and secretions of dogs. The concentrations of fleroxacin in prostatic secretion, prostatic interstitial fluid, and urine were many times higher than the MIC for most urinary tract pathogens (4, 10, 18).
To treat chronic bacterial prostatitis successfully, adequate drug levels must be achieved in the prostate. Penetration into the prostate is thought to be a passive process and depends on many physicochemical properties, such as degree of ionization, protein binding, and lipid solubility (22) . In this study, prostatic secretion/plasma and prostatic interstitial fluid/plasma concentration ratios close to 1 were not changed by increasing the plasma concentration of fleroxacin (Table 1 ). This suggests that the drug is passively diffused from plasma into the prostate and is in accordance with the theory proposed by Stamey et al. (22) . The ideal drug is uncharged at plasma pH, has low protein binding, and is lipophilic. In addition to these factors, the presence of a pH gradient across the prostatic epithelium is also important because of the phenomenon of ion trapping. When steady-state conditions have occurred, the highest drug concentration will be on the side of the biological membrane where most ionization occurs (i.e., charged plus uncharged). This is dependent on the pKa of the drug and the pH of the medium. This relation is expressed by the HendersonHasselbalch equation (22) . Whereas most antimicrobial drugs are either weak acids or bases (with 1 pKa), newer Figure 2 shows the calculated ionization curve for fleroxacin. As only the uncharged fraction is diffusible and active (22) , the lowest MIC is expected at the drug's isoelectric point. At both higher and lower pH values more drug is charged, resulting in an increased MIC. This pH effect was demonstrable in canine prostatic secretion and human urine ( Table 3 ) and suggests that it might be worthwhile to adjust pH to around 7.0 when treating urinary tract infections with fleroxacin. Interaction between body fluids and antimicrobial agents has been previously described (16, 21) . In our study, however, the investigated body fluids had no significant effect on MIC, indicating that the antibacterial activity of fleroxacin would be unaffected by prostatic secretion and urine.
The prostatic secretion/plasma ratio of fleroxacin ( Our findings, along with the favorable broad antimicrobial activity of fleroxacin, indicate that it might be a promising new drug for the treatment of urologic infections, including bacterial prostatitis.
